Infectious Disease · PANCE / PANRE

Lyme Disease

Tick-borne spirochetal infection (Borrelia burgdorferi) with characteristic erythema migrans and potential cardiac, neurologic, and arthritic complications.

Also known as: Lyme, Borrelia burgdorferi, borreliosis, erythema migrans, EM rash

Overview

Multisystem infection caused by Borrelia burgdorferi (US) and B. afzelii/B. garinii (Europe), transmitted by Ixodes scapularis (Northeast/Midwest US) and I. pacificus (West Coast) ticks. Course typically divided into early localized, early disseminated, and late disease.

Epidemiology

Most commonly reported vector-borne illness in the US (~30,000-40,000 reported cases yearly; CDC estimates true incidence ~476,000). Concentrated in Northeast, mid-Atlantic, upper Midwest, and Pacific Northwest. Peak incidence late spring through early fall.

Try two board-style Lyme Disease questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1Infectious DiseaseEasy
A 34-year-old woman presents to clinic with a rash on her right thigh that appeared 4 days ago. She recently returned from a hiking trip in Connecticut. She reports mild fatigue and a low-grade fever but no joint pain, headache, or neurologic symptoms. She has no known drug allergies and is not pregnant. On exam, vital signs are normal. There is a 9-cm annular erythematous patch with central clearing on the right anterior thigh. The remainder of the exam is unremarkable. Which of the following is the most appropriate first-line treatment?
  • AAzithromycin
  • BTrimethoprim-sulfamethoxazole
  • CDoxycycline
  • DCeftriaxone
Reveal answer & full explanation
Correct answer: C — Doxycycline
  • AAzithromycin
  • BTrimethoprim-sulfamethoxazole
  • CDoxycycline
  • DCeftriaxone

Why Doxycycline is correct

  • This patient has early localized Lyme disease, characterized by the classic erythema migrans rash (expanding annular lesion with central clearing) following tick exposure in an endemic area
  • Borrelia burgdorferi is transmitted by Ixodes scapularis ticks
  • First-line treatment for early localized Lyme disease in non-pregnant adults is oral doxycycline 100 mg twice daily for 10–14 days
  • Doxycycline is preferred because it also covers Anaplasma, a common co-infection

Why the others are wrong

  • A) Azithromycin — a second-line alternative with lower efficacy; reserved for patients who cannot take doxycycline, amoxicillin, or cefuroxime
  • B) Trimethoprim-sulfamethoxazole — has no reliable activity against Borrelia burgdorferi
  • D) Ceftriaxone — IV therapy reserved for neurologic Lyme disease, cardiac Lyme (high-grade AV block), or Lyme arthritis refractory to oral therapy; not indicated for uncomplicated erythema migrans

Additional high-yield points

  • IDSA/AAN/ACR 2020 guidelines support doxycycline as first-line for erythema migrans regardless of age, including children >8 years
Question 2Infectious DiseaseMedium
A 26-year-old man presents with a painless, circular, expanding skin lesion on his thigh with central clearing (bull's-eye appearance) 2 weeks after hiking in New England. He also has mild fatigue and arthralgia. Lyme serology (enzyme-linked immunosorbent assay (ELISA)) is positive. Western blot is positive for IgM and IgG bands. What is the most appropriate treatment?
  • ACeftriaxone 2 g IV daily for 21 days
  • BAzithromycin 500 mg daily for 7 days
  • CDoxycycline 100 mg twice daily (BID) for 10-14 days
  • DAmoxicillin 500 mg three times daily (TID) for 10-14 days
Reveal answer & full explanation
Correct answer: C — Doxycycline 100 mg twice daily (BID) for 10-14 days
  • ACeftriaxone 2 g IV daily for 21 days
  • BAzithromycin 500 mg daily for 7 days
  • CDoxycycline 100 mg twice daily (BID) for 10-14 days
  • DAmoxicillin 500 mg three times daily (TID) for 10-14 days

Why Doxycycline 100 mg twice daily (BID) for 10-14 days is correct

  • This is early localized Lyme disease with early dissemination signs (erythema migrans, arthralgia, fatigue) caused by Borrelia burgdorferi after tick exposure in New England
  • Two-tier serology (positive ELISA confirmed by Western blot with positive IgM and IgG bands) meets diagnostic criteria
  • Oral doxycycline 100 mg twice daily (BID) x 14-21 days is the preferred treatment; amoxicillin or cefuroxime are alternatives

Why the others are wrong

  • A) Ceftriaxone 2 g IV daily for 21 days — IV ceftriaxone is reserved for neurologic involvement (meningitis, cranial nerve palsy, radiculopathy), cardiac involvement (high-degree atrioventricular (AV) block), or refractory arthritis
  • B) Azithromycin 500 mg daily for 7 days — not a preferred agent for Lyme disease
  • D) Amoxicillin 500 mg three times daily (TID) for 10-14 days — is an acceptable alternative but not preferred over doxycycline in adults

Additional high-yield points

  • Single-dose prophylaxis is for tick bites within 72 hours — not for established disease
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Lyme Disease outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Outdoor exposure in endemic regions (hiking, gardening, hunting)
  • Tick attachment >36-48 hours (transmission rare with shorter attachment)
  • Age extremes (children 5-14, adults 50-69)

Pathophysiology

Spirochete enters skin during tick feeding, replicates locally producing erythema migrans, then disseminates hematogenously and via tissue migration to skin, joints, heart, and nervous system. Outer surface proteins (Osp) mediate immune evasion. Late arthritis driven by persistent inflammation and possible autoimmune mimicry; post-treatment Lyme disease syndrome remains incompletely understood.

Clinical presentation

Symptoms

  • Early localized (3-30 days post-bite): erythema migrans — expanding erythematous macule/patch, often with central clearing; ~70-80% of cases; flu-like symptoms (fatigue, myalgia, headache, low-grade fever)
  • Early disseminated (weeks-months): multiple secondary EM lesions, facial nerve palsy (often bilateral), lymphocytic meningitis, AV block (1st-3rd degree), myocarditis, migratory arthralgias
  • Late (months-years): monoarticular or oligoarticular arthritis (knee most common, large effusion), chronic neuroborreliosis (rare in US; encephalopathy, polyneuropathy), acrodermatitis chronica atrophicans (Europe)

Signs / physical exam

  • EM lesion >5 cm diameter, often warm but not particularly tender or pruritic
  • Facial droop (CN VII palsy), often bilateral — a key clue
  • Cardiac: variable AV block, sometimes requiring temporary pacing; usually resolves
  • Joint: large warm effusion (knee) with mild pain disproportionate to swelling

Classic findings

An expanding annular erythematous lesion >5 cm in an endemic area after summer tick exposure is sufficient for clinical diagnosis without serology.

Differential diagnosis

  • Southern tick-associated rash illness (STARI) — Lone star tick (Amblyomma americanum) bite in the Southeast; annular rash resembling EM but no Borrelia recovered; doxycycline empirically
  • Cellulitis — More tender, warm, sharply demarcated; lacks central clearing; rapidly progressive; treat for strep/staph
  • Tinea corporis — Scaling raised border, KOH positive; slower expansion
  • Erythema multiforme — Target lesions on extremities; mucosal involvement; HSV or drug trigger
  • Granuloma annulare — Chronic, non-tender annular plaques on dorsa of hands/feet; no exposure history
  • Septic arthritis — Acute monoarticular, very high WBC on arthrocentesis (>50,000); positive Gram stain/culture
  • Reactive arthritis — Post-GI/GU infection; conjunctivitis, urethritis, oligoarthritis; HLA-B27 association

Diagnostic workup

Diagnostic criteria

Clinical diagnosis based on EM in endemic exposure setting; otherwise two-tier serology required. Lyme arthritis: positive IgG Western blot virtually always present.

Labs

  • Two-tier serology (CDC): screening EIA → reflex Western blot (IgM if <30 days, IgG if >30 days); or modified two-tier with two EIAs (FDA cleared 2019)
  • Serology not indicated for isolated EM — treat clinically (antibodies often negative early)
  • Lyme PCR or culture from skin biopsy/synovial fluid — used selectively
  • CSF Lyme antibody index for suspected neuroborreliosis

Imaging

  • ECG if cardiac symptoms or high-risk exposure with constitutional symptoms
  • Joint ultrasound or MRI for effusion characterization if needed
  • Echo if myocarditis suspected

Diagnostic algorithm

StageTimingFeaturesTreatment
Early localized3-30 daysSingle EM, flu-like symptomsDoxycycline x 10 days
Early disseminatedWeeks-monthsMultiple EM, CN VII palsy, AV block, meningitisDoxycycline x 14-21 days; ceftriaxone if severe
LateMonths-yearsMono/oligoarthritis (knee), encephalopathyDoxycycline x 28 days; ceftriaxone if refractory
Clinical stages of Lyme disease with corresponding antibiotic regimens.

Treatment

First-line

  • Doxycycline 100 mg PO BID — preferred for early localized and most early disseminated disease (also covers anaplasmosis, common coinfection)
  • Doxycycline now considered safe in children <8 for short courses (<21 days; AAP)
  • Duration: 10 days for EM, 14 days for early neurologic/cardiac, 28 days for Lyme arthritis
  • Amoxicillin 500 mg PO TID or cefuroxime axetil 500 mg PO BID — alternatives if doxycycline contraindicated (e.g., pregnancy)
  • IV ceftriaxone 2 g daily for meningitis, encephalopathy, or high-grade AV block (PR >300 ms or symptomatic)

Tick bite prophylaxis

  • Single 200 mg doxycycline dose if all met: identified Ixodes scapularis, attached ≥36 h, prophylaxis within 72 h of removal, endemic area with local infection rate ≥20%, doxycycline not contraindicated

Pregnancy

  • Amoxicillin or cefuroxime; doxycycline traditionally avoided in pregnancy
  • No congenital Lyme syndrome established; treat as in non-pregnant adults otherwise

Second-line / adjunct

  • Azithromycin or clarithromycin — less effective; reserve for true beta-lactam and tetracycline contraindications
  • Persistent arthritis after 28 days of oral therapy → second 28-day oral course or IV ceftriaxone 14-28 days

Complications

  • Lyme arthritis (oligoarticular, mostly knee), persistent in ~10% despite antibiotics (antibiotic-refractory Lyme arthritis — autoimmune mechanism)
  • Lyme carditis with high-degree AV block
  • Cranial neuritis (especially bilateral CN VII), radiculoneuritis (Bannwarth syndrome — more common in Europe)
  • Post-treatment Lyme disease syndrome (PTLDS): persistent fatigue, arthralgia, cognitive symptoms >6 months; extended antibiotics not beneficial in randomized trials

PANCE pearls

  • Do NOT order serology in a patient with classic EM in an endemic area — treat clinically and avoid false negatives.
  • Bilateral facial palsy in a young adult in summer = Lyme until proven otherwise.
  • Coinfections (anaplasmosis, babesiosis) share Ixodes vector — consider in patients with cytopenias, hemolysis, or persistent fever on doxycycline (babesia not covered).
  • Lyme arthritis is monoarticular/oligoarticular and presents weeks to months later — large knee effusion with surprisingly little pain.
  • Single-dose doxycycline prophylaxis is the only validated tick-bite prophylaxis.

References

  • IDSA/AAN/ACR 2020 — Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease (Lantos et al., Clin Infect Dis 2021)
  • CDC 2019 — Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease (MMWR)
  • AAP — Red Book: Tetracycline use in children <8 for short courses

Practice Infectious Disease questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.